Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$109.02 USD

109.02
424,727

-1.89 (-1.70%)

Updated Apr 16, 2024 03:52 PM ET

After-Market: $108.92 -0.10 (-0.09%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can High Benefits and Expenses Affect Cigna (CI) Q3 Earnings?

by Zacks Equity Research

Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.

Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?

by Zacks Equity Research

Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?

by Zacks Equity Research

ImmunoGen (IMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

What's in the Cards for Encompass Health (EHC) in Q3 Earnings?

by Zacks Equity Research

Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.

What's in the Cards for Universal Health (UHS) in Q3 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q3 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.

Will Rising Costs Hurt HCA Healthcare's (HCA) Q3 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) third-quarter results are likely to reflect an increased occupancy rate and a lower average length of stay.

Sundeep Ganoria headshot

Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag

by Sundeep Ganoria

The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.

Can Growing Visits Aid Teladoc's (TDOC) Earnings in Q3?

by Zacks Equity Research

Teladoc's (TDOC) third-quarter results are likely to reflect growth in BetterHelp paying users.

Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study

by Zacks Equity Research

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.

Rimmi Singhi headshot

5 Value Stocks With High Earnings Yield to Boost Your Portfolio

by Rimmi Singhi

Unlock your portfolio value with high earnings yield value stocks like URBN, ADNT, OVV, JAZZ and RNR that will boost your returns.

Can Centene's (CNC) Q3 Earnings Beat on Membership Growth?

by Zacks Equity Research

Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.

Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication

by Zacks Equity Research

FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.

Does Jazz (JAZZ) Have the Potential to Rally 47.29% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Ligand (LGND) Acquires Certain Assets of Novan for $12.2M

by Zacks Equity Research

Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

by Zacks Equity Research

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

by Zacks Equity Research

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.

Why Is Jazz (JAZZ) Up 0.4% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus

by Zacks Equity Research

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

by Zacks Equity Research

Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.

Nektar (NKTR) Stock Surges 75% in a Week: Here's Why

by Zacks Equity Research

Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.

Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus

by Zacks Equity Research

Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.